An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2 -Catecholaminergic Polymorphic Ventricular Tachycardia

Kevin Ng, Erron W. Titus, Krystien V. Lieve, Thomas M. Roston, Andrea Mazzanti, Frederick H. Deiter, Isabelle Denjoy, Jodie Ingles, Jan Till, Tomas Robyns, Sean P. Connors, Christian Steinberg, Dominic J. Abrams, Benjamin Pang, Melvin M. Scheinman, J. Martijn Bos, Stephen A. Duffett, Christian Van Der Werf, Alice Maltret, Martin S. GreenJulie Rutberg, Seshadri Balaji, Julia Cadrin-Tourigny, Kate M. Orland, Linda M. Knight, Caitlin Brateng, Jeremy Wu, Anthony S. Tang, Allan C. Skanes, Jaimie Manlucu, Jeff S. Healey, Craig T. January, Andrew D. Krahn, Kathryn K. Collins, Kathleen R. Maginot, Peter Fischbach, Susan P. Etheridge, Lee L. Eckhardt, Robert M. Hamilton, Michael J. Ackerman, Ferran Rosés I. Noguer, Christopher Semsarian, Natalia Jura, Antoine Leenhardt, Michael H. Gollob, Silvia G. Priori, Shubhayan Sanatani, Arthur A.M. Wilde, Rahul C. Deo, Jason D. Roberts

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Genetic variants in calsequestrin-2 (CASQ2) cause an autosomal recessive form of catecholaminergic polymorphic ventricular tachycardia (CPVT), although isolated reports have identified arrhythmic phenotypes among heterozygotes. Improved insight into the inheritance patterns, arrhythmic risks, and molecular mechanisms of CASQ2-CPVT was sought through an international multicenter collaboration. Methods: Genotype-phenotype segregation in CASQ2-CPVT families was assessed, and the impact of genotype on arrhythmic risk was evaluated using Cox regression models. Putative dominant CASQ2 missense variants and the established recessive CASQ2-p.R33Q variant were evaluated using oligomerization assays and their locations mapped to a recent CASQ2 filament structure. Results: A total of 112 individuals, including 36 CPVT probands (24 homozygotes/compound heterozygotes and 12 heterozygotes) and 76 family members possessing at least 1 presumed pathogenic CASQ2 variant, were identified. Among CASQ2 homozygotes and compound heterozygotes, clinical penetrance was 97.1% and 26 of 34 (76.5%) individuals had experienced a potentially fatal arrhythmic event with a median age of onset of 7 years (95% CI, 6-11). Fifty-one of 66 CASQ2 heterozygous family members had undergone clinical evaluation, and 17 of 51 (33.3%) met diagnostic criteria for CPVT. Relative to CASQ2 heterozygotes, CASQ2 homozygote/compound heterozygote genotype status in probands was associated with a 3.2-fold (95% CI, 1.3-8.0; P=0.013) increased hazard of a composite of cardiac syncope, aborted cardiac arrest, and sudden cardiac death, but a 38.8-fold (95% CI, 5.6-269.1; P<0.001) increased hazard in genotype-positive family members. In vitro turbidity assays revealed that p.R33Q and all 6 candidate dominant CASQ2 missense variants evaluated exhibited filamentation defects, but only p.R33Q convincingly failed to dimerize. Structural analysis revealed that 3 of these 6 putative dominant negative missense variants localized to an electronegative pocket considered critical for back-to-back binding of dimers. Conclusions: This international multicenter study of CASQ2-CPVT redefines its heritability and confirms that pathogenic heterozygous CASQ2 variants may manifest with a CPVT phenotype, indicating a need to clinically screen these individuals. A dominant mode of inheritance appears intrinsic to certain missense variants because of their location and function within the CASQ2 filament structure.

Original languageEnglish (US)
Pages (from-to)932-947
Number of pages16
JournalCirculation
DOIs
StateAccepted/In press - 2020

Keywords

  • arrhythmias, cardiac
  • catecholaminergic polymorphic ventricular tachycardia
  • death, sudden, cardiac
  • genetics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2 -Catecholaminergic Polymorphic Ventricular Tachycardia'. Together they form a unique fingerprint.

Cite this